Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Market Movers
TipRanks 50 Index
AI Stocks
Largest Companies by Market Cap
ETFs
Top ETFs by Upside
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Ideas
Plans
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Trump Dashboard
New
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Economic Indicators
Inflation Rate
Unemployment Rate
Class Actions
Tools
Plans
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Screeners
Plans
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Dividends
Plans
My Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Experts
Plans
Portfolio
Plans
Trending News
More News >
News
Plans
Private Companies
Plans
Enterprise Solutions
Plans
Education
Personal Finance
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Advertise with Us
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
More
Plans
Plans & Pricing
Plans
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Screeners
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Ideas
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Research Tools
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Calculators
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividends
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Experts
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Market Movers
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
More
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Log Out
Advertisement
Advertisement
SYRE
Stock Latest News
Market News
3 ‘Strong Buy’ Stocks to Buy in Today’s Volatile Market, 2/23/2026, According to Top Analysts
2d ago
HOOD
NVDA
Premium
Ratings
Spyre Therapeutics: Rich 12-Month Catalyst Calendar and Differentiated IBD Portfolio Support Buy Rating
2d ago
SYRE
Premium
Ratings
Spyre Therapeutics: Accelerating Clinical Momentum, Validated Combination Strategy, and Strong Cash Runway Support Buy Rating
3d ago
SYRE
Premium
The Fly
Spyre Therapeutics rises 11.2%
5d ago
SYRE
Premium
Ratings
Spyre Therapeutics: Advancing Inflammatory Disease Pipeline and 2026 Proof‑of‑Concept Catalysts Support Buy/High Risk Rating and $64 Target
5d ago
SYRE
Premium
The Fly
Spyre Therapeutics reports Q4 EPS (70c) vs. (81c) last year
6d ago
SYRE
Premium
The Fly
Spyre Therapeutics files automatic mixed securities shelf
6d ago
SYRE
Premium
Company Announcements
Spyre Therapeutics Accelerates SKYLINE Trial and Bolsters Leadership
1M ago
8K
SYRE
Premium
The Fly
Spyre Therapeutics highlights 2026 priorities, appoints Cheveln as CCO
1M ago
SYRE
Premium
Ratings
Spyre Therapeutics: TL1A Blockade Opportunity in Rheumatology Underpins Buy Rating and $64 Target
2M ago
SYRE
Premium
The Fly
Spyre Therapeutics falls -7.4%
2M ago
SYRE
Premium
Ratings
Spyre Therapeutics: TL1A-Driven Inflammatory Arthritis Opportunity Underpins Buy Rating and $64 Target
2M ago
SYRE
Premium
The Fly
Spyre Therapeutics initiated with an Outperform at Mizuho
2M ago
SYRE
Premium
The Fly
Spyre Therapeutics initiated with a Buy at Citi
2M ago
SYRE
Premium
Ratings
Buy Rating for Spyre Therapeutics Driven by Strong Stock Performance and Promising Clinical Developments
3M ago
SYRE
Premium
The Fly
Carvana initiated, Zscaler downgraded: Wall Street’s top analyst calls
3M ago
ZS
CCI
Premium
Market News
3 Best Stocks to Buy Now, 12/1/2025, According to Top Analysts
3M ago
KTOS
LENZ
Premium
The Fly
Spyre Therapeutics upgraded to Buy from Hold at JonesResearch
3M ago
SYRE
Premium
Ratings
Spyre Therapeutics: Promising Innovations and Strong Financials Justify Buy Rating
4M ago
SYRE
Premium
Company Announcements
Spyre Therapeutics Reports Q3 2025 Financial Results
4M ago
SYRE
Premium
The Fly
Spyre Therapeutics reports Q3 EPS (15c), consensus (74c)
4M ago
SYRE
Premium
Company Announcements
Spyre Therapeutics Reports Positive Phase 1 Results for SPY003
4M ago
8K
SYRE
Show More
Trending
Indices
Stocks
ETFs
Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >
You need to enable JavaScript to run this app.
